Sheffield Matthew V, Yee Herman, Dorvault Christine C, Weilbaecher Katherine N, Eltoum Isam A, Siegal Gene P, Fisher David E, Chhieng David C
Department of Pathology, University of Alabama at Birmingham, 35249-6823, USA.
Am J Clin Pathol. 2002 Dec;118(6):930-6. doi: 10.1309/EWK9-LUPR-6BC5-1GXV.
We determined the sensitivity and specificity of 3 novel antibodies (microphthalmia transcription factor [Mitf], Melan-A, and tyrosinase) as markers for melanoma in cytologic preparations and compared the results with those of commonly used markers (S-100 protein [S-100] and HMB-45). We stained 72 cell blocks from 40 patients with melanoma and 32 with nonmelanocytic malignant neoplasms with antibodies against S-100, HMB-45, Mitf, Melan-A, and tyrosinase. Histologic correlation was available in more than 95% of cases. Nuclear stainingfor Mitf and cytoplasmic stainingfor S-100, HMB-45, Melan-A, and tyrosinase in more than 10% of tumor cells was considered positive. All 3 novel markers demonstrated sensitivity superior to S-100 and HMB-45. HMB-45, Melan-A, and Mitf demonstrated specificities of 97%. S-100 protein and tyrosinase were less specific. Sensitivity and specificity for the combination Mitf+/Melan-A+ were 95% and 100%, respectively, whereas they were 80% and 100%, respectively, for S-100+/HMB-45+. Mitf Melan-A, and tyrosinase are sensitive markersfor epithelioid melanoma. Mitf and Melan-A seem more specific than S-100 and tyrosinase. An antibody panel consisting of Mitf and Melan-A is superior to a panel of S-100 and HMB-45 in the diagnosis of melanoma in cytologic specimens.
我们测定了3种新型抗体（小眼畸形转录因子[Mitf]、黑色素A和酪氨酸酶）作为黑色素瘤细胞学标本标志物的敏感性和特异性，并将结果与常用标志物（S-100蛋白[S-100]和HMB-45）的结果进行比较。我们用抗S-100、HMB-45、Mitf、黑色素A和酪氨酸酶的抗体对40例黑色素瘤患者的72个细胞块和32例非黑素细胞性恶性肿瘤的细胞块进行染色。超过95%的病例有组织学相关性。肿瘤细胞中超过10%的Mitf核染色以及S-100、HMB-45、黑色素A和酪氨酸酶的胞质染色被视为阳性。所有3种新型标志物的敏感性均优于S-100和HMB-45。HMB-45、黑色素A和Mitf的特异性为97%。S-100蛋白和酪氨酸酶的特异性较低。Mitf+/黑色素A+组合的敏感性和特异性分别为95%和100%，而S-100+/HMB-45+组合的敏感性和特异性分别为80%和100%。Mitf、黑色素A和酪氨酸酶是上皮样黑色素瘤的敏感标志物。Mitf和黑色素A似乎比S-100和酪氨酸酶更具特异性。在细胞学标本中，由Mitf和黑色素A组成的抗体组合在黑色素瘤诊断方面优于由S-100和HMB-45组成的组合。
